- Home
- / RespireRx Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
RespireRx Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-29
Market Capitalization
$613.3 K
2024-10-29
Revenue
$86.9 K
FY, 2015
CreditSafe Score
?
Score changed on Jun 16, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.1M | 48.3K | 61.7K | 86.9K | ||||||||
| General and administrative expense | 3.2M | 1.9M | 933.0K | 3.8M | 3.6M | 5.3M | 2.5M | 1.5M | 1.1M | 2.7M | 1.9M | 1.1M |
| Operating expense total | 5.4M | 2.8M | 1.1M | 4.4M | 5.3M | 8.5M | 4.2M | 2.2M | 1.7M | 3.3M | 1.6M | |
| EBIT | (2.3M) | (7.3M) | (1.1M) | (4.4M) | (5.2M) | (8.5M) | (4.2M) | (2.2M) | (1.7M) | (3.3M) | (2.6M) | (1.6M) |
| EBIT margin, % | -72.6% | -15177.1% | -7059.7% | -6028.4% | ||||||||
| Interest income | 92.0 | 8.0 | ||||||||||
| Interest expense | 6.9K | 9.0 | 603.8K | |||||||||
| Net Income | (2.3M) | (7.6M) | (1.2M) | (2.7M) | (6.0M) | (9.2M) | (4.3M) | (2.6M) | (2.1M) | (4.3M) | (3.1M) | (2.1M) |